Abstract
Understanding the contribution of genetic variation to drug response can improve the delivery of precision medicine. However, genome-wide association studies (GWAS) for drug response are uncommon and are often hindered by small sample sizes. We present a high-throughput framework to efficiently identify eligible patients for genetic studies of adverse drug reactions (ADRs) using “drug allergy” labels from electronic health records (EHRs). As a proof-of-concept, we conducted GWAS for ADRs to 14 common drug/drug groups with 81,739 individuals from Vanderbilt University Medical Center’s BioVU DNA Biobank. We identified 7 genetic loci associated with ADRs at P < 5 × 10−8, including known genetic associations such as CYP2D6 and OPRM1 for CYP2D6-metabolized opioid ADR. Additional expression quantitative trait loci and phenome-wide association analyses added evidence to the observed associations. Our high-throughput framework is both scalable and portable, enabling impactful pharmacogenomic research to improve precision medicine.
Funding Information
  • National Institutes of Health (R01 HL133786)
  • National Institutes of Health (R35 GM131770)
  • National Institutes of Health (P50 GM115305)
  • National Institutes of Health (P50 GM115305)
  • National Institutes of Health (P50 GM115305)
  • National Institutes of Health (R01 HG010863)
  • National Institutes of Health (R01 AR073764)
  • U.S. Department of Veterans Affairs (1I01CX001741)
  • National Center for Advancing Translational Sciences (2UL1 TR000445-06)

This publication has 39 references indexed in Scilit: